Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TNFerade biologic · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| TNFerade biologic | DRUG | - |
Inclusion Criteria: * Age 70 or older with an ECOG performance status 0-2,or * Patients \> 18 years of age with ECOG performance status of 2 or greater, or * Patients \> 18 years of age unsuitable for concurrent chemotherapy or surgery due to: * Renal failure, or * Severe cardiopulmonary disease, o...
Top 20 of 57 competitors
TNFerade biologic was studied for the treatment of head and neck cancer. It was evaluated in Phase 1 clinical trials in patients with head and neck cancer and head and neck neoplasms, including one study in elderly or frail patients. It is an investigational therapy and is not approved for commercial use.
TNFerade biologic is being developed by Precigen, Inc., which trades under the ticker symbol PGEN. Precigen is the company associated with the clinical development of this investigational head and neck cancer therapy.
TNFerade biologic is in Phase 1 clinical development. Two Phase 1 trials have been conducted, and both are now completed. There are currently no active trials for TNFerade biologic. It remains an investigational agent and has not been approved by the FDA.
TNFerade biologic has been evaluated in two completed Phase 1 trials. NCT00496535 studied TNFerade biologic with concomitant radiotherapy, fluorouracil, and hydroxyurea in patients with head and neck cancer. NCT00496236 studied radiotherapy, cetuximab, and injections of TNFerade biologic in elderly or frail patients with head and neck cancer. Both trials were conducted in the United States.
No, TNFerade biologic is not FDA approved. It is an investigational therapy that has completed Phase 1 clinical development for head and neck cancer. Both of its Phase 1 trials are completed, and no active trials are ongoing.